Drugs / LY2405319
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01869959 | Apr → Jun 2009 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00481117 | Aug → Dec 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2405319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01869959 ↗ |
| Route | Subcutaneous | “Safety, Tolerability, PK and PD of LY2405319 After Multiple Subcutaneous Injections in Subjects With Type 2 Diabetes” NCT00481117 ↗ |